The FY21 Defense Appropriations Act provides funding to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service Members in current and future battlefield settings. The managing agent for the anticipated funding opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). http://cdmrp.army.mil/
The FY21 congressional language for the CRRP considered research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma. The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunity. This pre-announcement should not be construed as an obligation by the government. The FY21 CRRP funding opportunity announcement and General Submission Instructions/General Application Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the funding opportunity announcement is released.
The FY21 CRRP will solicit research applications addressing at least one of the Focus Areas described below. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.
Applications will be due to the Office of Sponsored Research and Programs at least five days prior to the sponsor deadline (when announced.)
Applications submitted to the FY21 CRRP must address one or more of the following Focus Areas:
- Solutions to enhance Warfighter readiness, such as solutions to address:
- Infectious diseases
- Sleep disorders
- Myalgic encephalomyelitis/chronic fatigue syndrome
- Service-related post-traumatic arthritis
- Solutions to enhance combat care delivery throughout the far-forward environment, such as:
- Telemedicine solutions that enable medical capabilities at far-forward battlespace locations worldwide
- Medical simulation technology that supports sustainment of critical skills and medical decision-making
- Freeze-dried plasma and platelets
- Ruggedized oxygen generation systems
- Solutions for the assessment of mild traumatic brain injury, to include portable devices
- Wound-care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care), such as:
- Multi-modal wound-care solutions that provide a combination of hemostasis, wound healing, infection prevention, and/or analgesia
- Traumatic wound care to prevent sepsis
- Repair and restoration of genitourinary injury and tissue damage
The Areas of Encouragement were identified as capability and knowledge gaps that are of high priority and programmatic relevance and can be found appended to the FY21 Rapid Development and Translational Research Award funding opportunity announcement. Investigators are strongly encouraged to propose research ideas that specifically address one of the FY21 Areas of Encouragement within each Focus Area (if applicable).
Rapid Development and Translational Research Award
Extramural and intramural applicants
Independent investigators at all academic levels (or equivalent)
- Submission of a preproposal is required; application submission is by invitation only.
- Different funding options are available. Applicants may apply to either the Phase 1 Base, or Phase 1 Base + Phase 2 Option. It is the responsibility of the Principal Investigator to select the funding option that is most appropriate for the research proposed.
- For applications proposing a Phase 1 Base + Phase 2 Option, each phase must be a distinct research effort with non-overlapping period of performance, research outcomes/milestones, and budget. Research products from the base award shall be leveraged in the subsequent option phase.
- Exercise of the Phase 2 Option is contingent on the availability of sufficient future congressional appropriations to the CRRP, alignment of the proposed research during the Phase 2 Option to that fiscal year’s congressional language, and acceptable performance by the recipients.
- Supports research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.
- Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate.
- Phase 0 and phase 1 clinical trials are allowed. Phase 2 and phase 3 clinical trials are not permitted under this funding opportunity announcement.
Phase 1 Base
- Maximum funding of $1,800,000 for total costs (to include direct and indirect costs)
- Maximum period of performance is 2 years
Phase 1 Base + Phase 2 Option
- Maximum funding of $1,800,000 (Phase 1 Base) and $1,000,000 (Phase 2 Option) for total costs (to include direct and indirect costs)
- Maximum period of performance is 2 years for Phase 1 Base and 1 year for Phase 2 Option
For questions and help with your proposal, contact the Office of Sponsored Research and Programs via email at firstname.lastname@example.org.